接受根治性放疗联合同步化疗的下咽癌的临床疗效
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy.
作者信息
Sakaguchi Masakuni, Maebayashi Toshiya, Aizawa Takuya, Ishibashi Naoya, Saito Tsutomu
机构信息
Department of Radiology, Nihon University School of Medicine, Tokyo, Japan
Department of Radiology, Nihon University School of Medicine, Tokyo, Japan.
出版信息
Anticancer Res. 2017 Feb;37(2):941-947. doi: 10.21873/anticanres.11403.
AIM
To evaluate clinical outcomes of concurrent chemoradiotherapy (CCRT) in patients with hypopharyngeal cancer (HPC).
PATIENTS AND METHODS
This retrospective study included 80 patients (75 males) aged 48 to 78 years (median=66 years) with a histological diagnosis of HPC. The 5-fluorouracil and cisplatin (FP) regimen was used until 2007 and then switched to the docetaxel, cisplatin, and 5-fluorouracil (TPF) regimen. Radiotherapy was administered to a total dose of 60 to 72 Gy (median=66 Gy).
RESULTS
The 5-year overall survival and disease-free survival rates were 49.3% and 60.7%, respectively. Improved disease-free survival was associated with lower N-stage (hazard ratio=0.249; 95% confidence interval=0.096-0.643; p=0.041).
CONCLUSION
There were no significant differences in overall and disease-free survival between patients receiving CCRT with the TPF regimen and those who received FP for a long period of treatment but did not finish two courses.
目的
评估同步放化疗（CCRT）治疗下咽癌（HPC）患者的临床疗效。
患者与方法
这项回顾性研究纳入了80例年龄在48至78岁（中位年龄 = 66岁）、经组织学诊断为下咽癌的患者（75例男性）。2007年之前使用氟尿嘧啶和顺铂（FP）方案，之后改为多西他赛、顺铂和氟尿嘧啶（TPF）方案。放疗总剂量为60至72 Gy（中位剂量 = 66 Gy）。
结果
5年总生存率和无病生存率分别为49.3%和60.7%。无病生存率的提高与较低的N分期相关（风险比 = 0.249；95%置信区间 = 0.096 - 0.643；p = 0.041）。
结论
接受TPF方案同步放化疗的患者与长期接受FP方案但未完成两个疗程的患者相比，总生存率和无病生存率无显著差异。
Zotero 插件